Compare Novo Nordisk A/S (NVO) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rigetti Computing Inc — how do they compare? Novo Nordisk A/S trades at $44.78 (market cap $200.69B), while Rigetti Computing Inc trades at $15.33 (market cap $5.28B). The key difference: Novo Nordisk A/S is far larger — about 38× Rigetti Computing Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| NVO | RGTI | |
|---|---|---|
Market Cap | $200.69B | $5.28B |
Sector | Health | Technology |
52-Week High | $63.98 | $56.34 |
52-Week Low | $35.29 | $12.90 |
Enterprise Value | $215.49B | $4.89B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Rigetti Computing (RGTI) trades at $15.81, up 4.01% today, amid mixed signals with bearish technical indicators but strong analyst support. The stock shows significant fundamental challenges with a P/S ratio of 391.11 and deeply negative profit margins (-1,787.4% net income margin), though recent government funding of $100 million provides crucial support. Technical analysis indicates bearish momentum with support at $15 and resistance at $17.
The outlook remains speculative with substantial execution risks and widening losses, offset by government backing and quantum computing potential. Investment opportunity hinges on long-term technology commercialization, while immediate risks include persistent cash burn and competitive pressures in the nascent quantum sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
